Linked Life Data

3891900

Source:http://linkedlifedata.com/resource/pubmed/id/3891900

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3891900rdf:typepubmed:Citationlld:pubmed
pubmed-article:3891900lifeskim:mentionsumls-concept:C0376325lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0042769lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0199176lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0305052lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0456603lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:3891900lifeskim:mentionsumls-concept:C0205473lld:lifeskim
pubmed-article:3891900pubmed:issue2lld:pubmed
pubmed-article:3891900pubmed:dateCreated1985-8-20lld:pubmed
pubmed-article:3891900pubmed:abstractTextSeroconversion to hepatitis A virus was studied in a sub sample of 802 Israeli military recruits (611 men and 191 women) who were taking part in a randomised controlled trial of pre-exposure immune serum globulin (ISG) for the prevention of viral hepatitis. On intake into the service 35% of the men and 47% of the women were negative to hepatitis. A virus antibody (anti-HAV). After three years 7 of 71 men (9.9%) who had not received pre-exposure ISG had become positive to anti-HAV compared to 2 of 83 (2.4%) who had received it; the statistical significance of this difference was p = 0.052. At two years 2 of 30 women (6.7%) who had not received ISG had converted compared to 1 of 43 (2.3%) who had received ISG (p = 0.37). Pooling the sexes gave conversion rates of 8.9% in those not immunised and 2.4% in those immunised (p = 0.029). The sex adjusted odds ratio was 4.0 (95% confidence limits 1.3-19.0). The morbidity rates for clinical non B hepatitis over the three year period among 12 835 men were 7.2 per 1000 in those not immunised and 3.6 per 1000 in those immunised (p = 0.004). Point estimates of the ratio of clinical hepatitis to seroconversion in men ranged from 0.25 to 0.30. It is concluded that pre-exposure administration of ISG effectively prevented clinical expression of viral hepatitis, apparently reduced seroconversion, and did not induce passive-active immunisation.lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:languageenglld:pubmed
pubmed-article:3891900pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:citationSubsetIMlld:pubmed
pubmed-article:3891900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891900pubmed:statusMEDLINElld:pubmed
pubmed-article:3891900pubmed:monthJunlld:pubmed
pubmed-article:3891900pubmed:issn0143-005Xlld:pubmed
pubmed-article:3891900pubmed:authorpubmed-author:Bar-ShanySSlld:pubmed
pubmed-article:3891900pubmed:authorpubmed-author:KarkJ DJDlld:pubmed
pubmed-article:3891900pubmed:authorpubmed-author:NiliEElld:pubmed
pubmed-article:3891900pubmed:authorpubmed-author:ShorSSlld:pubmed
pubmed-article:3891900pubmed:authorpubmed-author:MerlinskiLLlld:pubmed
pubmed-article:3891900pubmed:issnTypePrintlld:pubmed
pubmed-article:3891900pubmed:volume39lld:pubmed
pubmed-article:3891900pubmed:ownerNLMlld:pubmed
pubmed-article:3891900pubmed:authorsCompleteYlld:pubmed
pubmed-article:3891900pubmed:pagination117-22lld:pubmed
pubmed-article:3891900pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:meshHeadingpubmed-meshheading:3891900-...lld:pubmed
pubmed-article:3891900pubmed:year1985lld:pubmed
pubmed-article:3891900pubmed:articleTitleSerological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin.lld:pubmed
pubmed-article:3891900pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3891900pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3891900pubmed:publicationTypeRandomized Controlled Triallld:pubmed